RenovoRx Stock Forecast
NASDAQ: RNXTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
RNXT analyst consensus
Consensus (4 analysts)
none
Avg. price target
$7.13+436.09%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering RenovoRx (2026-10-09), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $7.13, with a high estimate of $14.50 and a low estimate of $3.00. The average target implies upside of 436.1% from the current price of $1.33.
The spread between the highest and lowest targets is 383.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RNXT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $3.00 | +125.56% |
| Average target | $7.13 | +436.09% |
| High target | $14.50 | +990.23% |